GeNeuro Reports 2023 Half-Year Results and Provides Corporate Update Oct 2, 2023 01:30AM
The EIB and GeNeuro Sign a EUR 25 Million Credit Line Backed by InvestEU to Support Clinical Developments Against Long-COVID Mar 7, 2023 01:30AM
GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab Nov 16, 2022 01:30AM
GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab Nov 16, 2022 01:30AM
GeNeuro: Study Confirming the Key Role of Human Endogenous Retroviruses (HERV-K) for ALS Published in "Annals of Neurology", a Leading Scientific Journal Jul 20, 2022 01:30AM


May 12, 2022 03:14AM GeNeuro Announces Successful €7.7 Million Private Placement
Apr 15, 2022 01:30AM GeNeuro: Financial Information for the First Quarter 2022
Mar 21, 2022 02:30AM ProTEct-MS Phase 2 Trial Confirms Safety of Higher Doses of Temelimab and Synergistic Potential to Address Neurodegeneration on Top of Anti-inflammatory Treatment in Multiple Sclerosis
Dec 20, 2021 01:30AM Presentation at The Lancet Summit on GeNeuro’s Novel anti-HERV-K Antibody for Amyotrophic lateral sclerosis  
Sep 24, 2021 09:00AM GeNeuro and Northwestern University Enter Into a Research Collaboration on HERV-W ENV in Long-haul COVID
Jan 26, 2021 01:30AM GeNeuro Receives French State Grant to Accelerate Research Into the Role of HERV Proteins in COVID-19
Sep 18, 2018 01:30AM GeNeuro Regains Worldwide Rights ex US and Japan to GNbAC1 in Multiple Sclerosis from Servier
Sep 18, 2018 01:30AM GeNeuro Regains Worldwide Rights ex US and Japan to GNbAC1 in Multiple Sclerosis from Servier
Mar 26, 2018 01:30AM GeNeuro and Servier Announce Successful 12-Month Results in Neuroprotection for Phase 2b CHANGE-MS Study with GNbAC1 in Multiple Sclerosis